RenoVate Therapeutics

Company Overview

Snapshot

Founded in February 2022 by David C., Benjamin Dekel, Daniel Clayman, and Dorit Omer, RenoVate Therapeutics operates with 1–10 employees. The company has secured funding across one round from HCS Capital. RenoVate Therapeutics is actively developing regenerative biomolecules aimed at kidney repair and rejuvenation.

Business overview

RenoVate Therapeutics is focused on developing regenerative biomolecules designed to repair and rejuvenate kidneys. The company utilizes proprietary technology to derive these biomolecules from cells expanded from a patient's own urine. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, RenoVate Therapeutics serves the healthcare market, targeting both providers and patients with its biotechnology solutions.

Company Intelligence Q&A

When was RenoVate Therapeutics founded?

RenoVate Therapeutics was founded in February 2022.

Who are the founders of RenoVate Therapeutics?

The founders of RenoVate Therapeutics are David C., Benjamin Dekel, Daniel Clayman, and Dorit Omer.

What is RenoVate Therapeutics' primary focus?

RenoVate Therapeutics is developing regenerative biomolecules to repair and rejuvenate kidneys.

What technology does RenoVate Therapeutics use?

RenoVate Therapeutics uses proprietary technology to expand cells from a patient's own urine to derive regenerative biomolecules.

Which investor participated in RenoVate Therapeutics' funding round?

In March 2022, HCS Capital participated as a lead investor in.